1-20 of 28
Joan Albanell
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PO4-12-07: INSTITUTIONAL EXPERIENCE IN PATIENTS WITH EARLY BREAST CANCER WHO RECEIVED CARDIOTOXIC THERAPY IN CARDIONCOLOGY UNIT

Tamara Martos, Laia Carla Belarte-Tornero, Mireia Ble, Eva Gimeno, Laura Sanhauja, Felicidad Martines-Medina, Maria Martinez-García, Maria Castro-Henriques, Joan Albanell, Sonia Servitja
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO4-12-07.
https://doi.org/10.1158/1538-7445.SABCS23-PO4-12-07
Published: 02 May 2024
View articletitled, Abstract PO4-12-07: INSTITUTIONAL EXPERIENCE IN PATIENTS WITH EARLY BREAST CANCER WHO RECEIVED CARDIOTOXIC THERAPY IN CARDIONCOLOGY UNIT
Journal Articles

Abstract PS17-04: Clinical and Genomic Features of ER-Positive/HER2-negative Metastatic Breast Cancer in AURORA Molecular Screening Initiative (BIG 14-01): Mechanisms of Endocrine Therapy Resistance and Implications for Adjuvant Approaches

Angel Guerrero-Zotano, Matteo Benelli, Alexandre Irrthum, David Cameron, Lorenzo Ferrando, Dario Romagnoli, Marta Paoli, Arnau Llinas, Maya Dadiani, Danai Fimereli, Mafalda Oliveira, Carmela Caballero, Thayane Crestani, Elisa Agostinetto, Diogo Martins-Branco, Florentine Hilbers, Einav Gal-Yam, Marija Balic, Fatima Cardoso, Jorge Reis-Filho, Christos Sotiriou, Giuseppe Curigliano, Barbro Linderholm, Evandro de Azambuja, Susan Knox, Cristina Rotaru, Eva Ciruelos, Nancy E Davidson, Giuseppe Viale, Donatienne Taylor, Jean-Luc Canon, Lourdes Calvo, Joan Albanell, Marco Colleoni, Caroline Duhem, Nadia Harbeck, Catherine Herremans, Sibylle Loibl, Sandrine Marreaud, Elsemieke Scheepers, Alice Raimbault, Theodora Goulioti, Andrea Vingiani, Chiara Biagioni, Sebastian Vosberg, Gabriele Zoppoli, Jose Seoane, David Venet, Philippe Aftimos, Martine Piccart
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PS17-04.
https://doi.org/10.1158/1538-7445.SABCS23-PS17-04
Published: 02 May 2024
View articletitled, Abstract PS17-04: Clinical and Genomic Features of ER-Positive/HER2-negative Metastatic Breast Cancer in AURORA Molecular Screening Initiative (BIG 14-01): Mechanisms of Endocrine Therapy Resistance and Implications for Adjuvant Approaches
Journal Articles

Abstract 2493: Prospective evaluation of predictive biomarkers for Palbociclib (P) and endocrine therapy (ET) benefit in hormone receptor (HR)-positive [+]/human epidermal growth factor receptor 2 (HER2)-negative [-] advanced breast cancer (ABC) patients (pts) from PARSIFAL clinical trial: The transFAL sub-study

Joan Albanell, Angelo Gámez Pozo, Carlos L. Arteaga, Meritxell Bellet, Federico Rojo, Abel González, Beatriz Bellosillo, Violeta Serra, Petra Gener, José Antonio Guerrero, Laura López-Montero, Mario Mancino, Jose Rodríguez-Morató, Leonardo Mina, José Manuel Pérez-García, Javier Cortés, Antonio Llombart-Cussac
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 2493.
https://doi.org/10.1158/1538-7445.AM2024-2493
Published: 22 March 2024
View articletitled, Abstract 2493: Prospective evaluation of predictive biomarkers for Palbociclib (P) and endocrine therapy (ET) benefit in hormone receptor (HR)-positive [+]/human epidermal growth factor receptor 2 (HER2)-negative [-] advanced breast cancer (ABC) patients (pts) from PARSIFAL clinical trial: The transFAL sub-study
Journal Articles

Abstract PD13-10: PD13-10 Impact of Proton Pump Inhibitors (PPI) on Palbociclib (PAL) Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (HR+/HER2- ABC): Exploratory Analysis of the PARSIFAL Trial

Serena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet Ezquerra, Florence Dalenc, Miguel Gil Gil, Manuel Ruiz Borrego, Joaquín Gavilá, Miguel Sampayo-Cordero, Elena Aguirre, Peter Schmid, Frederik Marmé, Joseph Gligorov, Andreas Schneeweiss, Joan Albanell, Pilar Zamora, Duncan Wheatley, Eduardo Martínez De Dueñas, Vicente Carañana, Kepa Amillano, Andrea Malfettone, Javier Cortés, Antonio Llombart-Cussac
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): PD13-10.
https://doi.org/10.1158/1538-7445.SABCS22-PD13-10
Published: 01 March 2023
View articletitled, Abstract PD13-10: PD13-10 Impact of Proton Pump Inhibitors (PPI) on Palbociclib (PAL) Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (HR+/HER2- ABC): Exploratory Analysis of the PARSIFAL Trial
Journal Articles

Abstract 423: Pooled analysis of matching score and patient outcome in I-PREDICT and WINTHER studies

David Casadevall, Michal Marczyk, Xavier Monzonis, Lajos Pusztai, Joan Albanell
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 423.
https://doi.org/10.1158/1538-7445.AM2021-423
Published: 01 July 2021
View articletitled, Abstract 423: Pooled analysis of matching score and patient outcome in I-PREDICT and WINTHER studies
Journal Articles

Abstract 1075: AXL is a potential druggable target in trastuzumab resistance in HER2+ breast cancer patients

Anna Adam-Artigues, Raimundo Cervera, Enrique Javier Arenas, Fara Brasó-Maristany, Alex Martinez-Sabadell, Eduardo Tormo, Cristina Hernando, Maria Teresa Martinez, Soraya Simon, Jesús Poveda, Octavio Burgués, Ana Rovira, Federico Rojo, Joan Albanell, Begoña Bermejo, Ana Lluch, Pilar Eroles, Aleix Prat, Joaquin Arribas, Juan Miguel Cejalvo
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1075.
https://doi.org/10.1158/1538-7445.AM2021-1075
Published: 01 July 2021
View articletitled, Abstract 1075: AXL is a potential druggable target in trastuzumab resistance in HER2+ breast cancer patients
Journal Articles

Abstract PS10-17: Palbociclib (P) in combination with fulvestrant (F) or letrozole (L) in endocrine-sensitive patients (pts) with hormone receptor (HR)[+]/HER2[-] metastatic breast cancer (MBC): detailed safety analysis from a multicenter, randomized, open-label, phase II trial (PARSIFAL)

José Manuel Pérez-García, Antonio Llombart-Cussac, Meritxell Bellet, Florence Dalenc, Miguel J. Gil Gil, Manuel Ruiz Borrego, Joaquín Gavilá, Miguel Sampayo-Cordero, Elena Aguirre, Peter Schmid, Frederik Marmé, Serena Di Cosimo, Joseph Gligorov, Andreas Schneeweiss, Joan Albanell, Pilar Zamora, Duncan Wheatley, Eduardo Martínez-De Dueñas, Vicente Carañana, Kepa Amillano, Andrea Malfettone, Javier Cortés
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS10-17.
https://doi.org/10.1158/1538-7445.SABCS20-PS10-17
Published: 15 February 2021
View articletitled, Abstract PS10-17: Palbociclib (P) in combination with fulvestrant (F) or letrozole (L) in endocrine-sensitive patients (pts) with hormone receptor (HR)[+]/HER2[-] metastatic breast cancer (MBC): detailed safety analysis from a multicenter, randomized, open-label, phase II trial (PARSIFAL)
Journal Articles

Abstract PS10-27: A phase II proof-of-concept study of palbociclib (P) rechallenge in patients (pts) with hormone receptor (HR)[+]/HER2[-] metastatic breast cancer (MBC) and clinical benefit to prior P-based treatment (BIOPER)

Antonio Llombart-Cussac, Javier Cortés, Beatriz Bellosillo Paricio, Miguel Gil Gil, Giuseppe Curigliano, José Manuel Pérez-García, Laura Comerma Blesa, Manuel Ruíz Borrego, Enrique Espinosa, Lourdes Calvo, Begoña Bermejo, Meritxell Bellet, Federico Rojo Todo, Juan de la Haba, Vanesa Quiroga, Alessandro Minisini, Ana Santaballa, Miguel Sampayo, Andrea Malfettone, Joan Albanell
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS10-27.
https://doi.org/10.1158/1538-7445.SABCS20-PS10-27
Published: 15 February 2021
View articletitled, Abstract PS10-27: A phase II proof-of-concept study of palbociclib (P) rechallenge in patients (pts) with hormone receptor (HR)[+]/HER2[-] metastatic breast cancer (MBC) and clinical benefit to prior P-based treatment (BIOPER)
Journal Articles

Abstract P6-03-05: AXL-HER2 dimer as mechanism of anti-HER2 acquired resistance in HER2 amplified brest cancer models: A new step towards precision medicine

Anna Adam-Artigues, Eduardo Tormo, Raimundo Cervera, Federico Rojo, Alejandro Pérez-Fidalgo, Sandra Zazo, Paula González-Alonso, Cristina Hernándo, María Teresa Martínez, Valentina Gambardella, Jesús Poveda, Soraya Simón, Belén Ortega, Santiago Moragón, Ana Rovira, Joan Albanell, Octavio Burgués, Begoña Bermejo, Pilar Eroles, Ana Lluch, Juan Miguel Cejalvo
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P6-03-05.
https://doi.org/10.1158/1538-7445.SABCS19-P6-03-05
Published: 15 February 2020
View articletitled, Abstract P6-03-05: AXL-HER2 dimer as mechanism of anti-HER2 acquired resistance in HER2 amplified brest cancer models: A new step towards precision medicine
Journal Articles

Abstract P4-10-17: Baseline and pharmacodynamic changes of circulating exosomal microRNAs predict early versus late progression to palbociclib plus endocrine therapy in patients with metastatic breast cancer. A sub-analysis of the PARSIFAL-1 trial

David Casadevall, Joan Albanell Mestres, Federico Rojo, Beatríz Bellosillo, Abel González, Violeta Serra, Meritxell Bellet, Miguel Angel Gil, Miquel Angel Pujana, Angelo Gámez, Enrique Espinosa, Peter Schmid, Joseph Gligorov, Frederik Marmé, Carlos L. Arteaga, Leonardo Mina, Andrea Malfettone, Miguel Sampayo, José Manuel Pérez-García, Javier Cortés, Antonio Llombart-Cussac
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P4-10-17.
https://doi.org/10.1158/1538-7445.SABCS19-P4-10-17
Published: 15 February 2020
View articletitled, Abstract P4-10-17: Baseline and pharmacodynamic changes of circulating exosomal microRNAs predict early versus late progression to palbociclib plus endocrine therapy in patients with metastatic breast cancer. A sub-analysis of the PARSIFAL-1 trial
Journal Articles

Abstract CT219: Neoadjuvant letrozole and palbociclib in stage II-IIIB HR[+]/HER2[-] breast cancer with Oncotype DX Recurrence Score® (RS) 18-25 or 26-100. Analysis of RS changes at surgery (DxCARTES trial)

Antonio Llombart Cussac, José Pérez-García, Ángel Guerrero, Begoña Bermejo, Miguel Gil, Vicente Carañana, Serafín Morales, Juan de la Haba, María Fernández, Emilio Alba, Ander Urruticoechea, Lourdes Calvo, Mireia Margeli, Antonio Antón, Manuel Ruíz Borrego, Joan Albanell, Pedro Sánchez Rovira, Meritxell Bellet, Sofia Braga, Passos Coelho, Miguel Abreu, Javier Cortés
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT219.
https://doi.org/10.1158/1538-7445.AM2019-CT219
Published: 01 July 2019
View articletitled, Abstract CT219: Neoadjuvant letrozole and palbociclib in stage II-IIIB HR[+]/HER2[-] breast cancer with Oncotype DX Recurrence Score® (RS) 18-25 or 26-100. Analysis of RS changes at surgery (DxCARTES trial)
Journal Articles

Abstract LB-143: Th1/Th2 and inflammatory cytokines as biomarkers of response to ipilimumab in small cell lung cancer (SCLC) patients

Max Hardy-Werbin, Pedro Rocha, Oriol Arpí, Álvaro Taus, Xavier Durán Jordà, Deborah Joseph-Pietras, Ana Rovira, Joan Albanell, Christian Ottensmeier, Edurne Arriola
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): LB-143.
https://doi.org/10.1158/1538-7445.AM2018-LB-143
Published: 01 July 2018
View articletitled, Abstract LB-143: Th1/Th2 and inflammatory cytokines as biomarkers of response to ipilimumab in small cell lung cancer (SCLC) patients
Journal Articles

Abstract 2913: Emergence of RAS or EGFR mutant clones affects duration of response to EGFR blockade in colorectal cancers

Sabrina Arena, Beth Van Emburgh, Giulia Siravegna, Luca Lazzari, Giovanni Crisafulli, Giorgio Corti, Benedetta Mussolin, Federica Baldi, Michela Buscarino, Alice Bartolini, Emanuele Valtorta, Joana Vidal, Beatriz Bellosillo, Giovanni Germano, Filippo Pietrantonio, Agostino Ponzetti, Joan Albanell, Salvatore Siena, Andrea Sartore-Bianchi, Federica Di Nicolantonio, Clara Montagut, Alberto Bardelli
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 2913.
https://doi.org/10.1158/1538-7445.AM2017-2913
Published: 01 July 2017
View articletitled, Abstract 2913: Emergence of RAS or EGFR mutant clones affects duration of response to EGFR blockade in colorectal cancers
Journal Articles

Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer

Juan M. Cejalvo, Eduardo Martínez de Dueñas, Patricia Galván, Susana García-Recio, Octavio Burgués Gasión, Laia Paré, Silvia Antolín, Rosella Martinello, Isabel Blancas, Barbara Adamo, Ángel Guerrero-Zotano, Montserrat Muñoz, Paolo Nucíforo, María Vidal, Ramón M. Pérez, José I. Chacón López-Muniz, Rosalía Caballero, Vicente Peg, Eva Carrasco, Federico Rojo, Charles M. Perou, Javier Cortés, Vincenzo Adamo, Joan Albanell, Roger R. Gomis, Ana Lluch, Aleix Prat
Journal: Cancer Research
Series: Author Choice
Cancer Res (2017) 77 (9): 2213–2221.
https://doi.org/10.1158/0008-5472.CAN-16-2717
Published: 30 April 2017
View articletitled, Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer
Open the PDF for Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract 2149: The anti-EGFR antibody mixture Sym004 overcomes acquired resistance to cetuximab in colorectal cancer

Francisco J. Sanchez-Martin, Alba Dalmases, Beatriz Bellosillo, Guillem Argiles, Mariona Gelabert, Israel Cañadas, Joana Vidal, Giulia Siravegna, Sabrina Arena, Klaus Koefoed, Laura Visa, Oriol Arpí, Ivan D. Horak, Mar Iglesias, Christopher Stroh, Michael Kragh, Ana Rovira, Joan Albanell, Alberto Bardelli, Josep Tabernero, Clara Montagut
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 2149.
https://doi.org/10.1158/1538-7445.AM2016-2149
Published: 15 July 2016
View articletitled, Abstract 2149: The anti-EGFR antibody mixture Sym004 overcomes acquired resistance to cetuximab in colorectal cancer
Journal Articles

Abstract 3443: A new medical tool to discriminate on a radiotherapy concomitant treatment for non-small cell lung cancer patients

Maria I. Ibáñez-de-Cáceres, Olga Pernía, Cristobal Belda-Iniesta, Olga Vera, Julia Jimenez, Carlos Rodriguez, Javier Soto, Javier de Castro, Teresa Macias, Federico Rojo, Joan Albanell, Rosario Perona
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 3443.
https://doi.org/10.1158/1538-7445.AM2015-3443
Published: 01 August 2015
View articletitled, Abstract 3443: A new medical tool to discriminate on a radiotherapy concomitant treatment for non-small cell lung cancer patients
Journal Articles

Abstract 3588: Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer

Luca Lazzari, Sabrina Arena, Beatriz Bellosillo, Giulia Siravegna, Alejandro Martínez, Israel Cañadas, Noelia Ferruz, Mariangela Russo, Sandra Misale, Iria González, Mar Iglesias, Elena Gavilan, Giorgio Corti, Sebastijan Hobor, Giovanni Crisafulli, Marta Salido, Juan Sánchez, Alba Dalmases, Joaquim Bellmunt, Gianni De Fabritiis, Ana Rovira, Federica Di Nicolantonio, Joan Albanell, Alberto Bardelli, Clara Montagut
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 3588.
https://doi.org/10.1158/1538-7445.AM2015-3588
Published: 01 August 2015
View articletitled, Abstract 3588: Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer
Journal Articles

Abstract P6-08-10: Prospective study of the impact of the Prosigna™ assay on adjuvant clinical decision-making in women with estrogen receptor-positive, HER2-negative, node-negative breast cancer: A GEICAM study

Miguel Martín, Milagros González-Rivera, Serafín Morales, Juan de la Haba, Lucía González-Cortijo, Luis Manso, Joan Albanell, Antonio González-Martín, Sónia González, Angels Arcusa, Luis de la Cruz-Merino, Federico Rojo, Maria Vidal, Uxue Goicoechea, Patricia Galván, Rosalía Caballero, Eva Carrasco, Steven Michalopoulos, John Hornberger, Aleix Prat
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P6-08-10.
https://doi.org/10.1158/1538-7445.SABCS14-P6-08-10
Published: 01 May 2015
View articletitled, Abstract P6-08-10: Prospective study of the impact of the Prosigna™ assay on adjuvant clinical decision-making in women with estrogen receptor-positive, HER2-negative, node-negative breast cancer: A GEICAM study
Journal Articles

Snail1-Expressing Fibroblasts in the Tumor Microenvironment Display Mechanical Properties That Support Metastasis

Jelena Stanisavljevic, Jordina Loubat-Casanovas, Mercedes Herrera, Tomás Luque, Raúl Peña, Ana Lluch, Joan Albanell, Félix Bonilla, Ana Rovira, Cristina Peña, Daniel Navajas, Federico Rojo, Antonio García de Herreros, Josep Baulida
Journal: Cancer Research
Cancer Res (2015) 75 (2): 284–295.
https://doi.org/10.1158/0008-5472.CAN-14-1903
Published: 14 January 2015
View articletitled, Snail1-Expressing Fibroblasts in the Tumor Microenvironment Display Mechanical Properties That Support Metastasis
Open the PDF for Snail1-Expressing Fibroblasts in the Tumor Microenvironment Display Mechanical Properties That Support Metastasis in another window
Includes: Multimedia, Supplementary data
Journal Articles

Abstract 2366: Role of MKP1 in skin carcinogenesis

Rosario Perona, Vanessa Rodriguez-Fanjul, Sandra Zazo, Isabel Sanchez-Perez, Rafael Bragado, Ana Rovira, Joan Albanell, Federico Rojo
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 2366.
https://doi.org/10.1158/1538-7445.AM2012-2366
Published: 15 April 2012
View articletitled, Abstract 2366: Role of MKP1 in skin carcinogenesis